

University of Groningen

Oncogenic variants guiding treatment in thoracic malignancies

Meng, Pei

DOI:
[10.33612/diss.160074057](https://doi.org/10.33612/diss.160074057)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Meng, P. (2021). *Oncogenic variants guiding treatment in thoracic malignancies*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.160074057>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Propositions Belonging to the PhD thesis Oncogenic variants guiding treatment in thoracic malignancies

1. Customized RNA-based all-in-one assay has a good performance in testing multiple therapeutic guiding mutations and may be applicable in a clinical diagnostic setting. (this thesis)
2. Tumor-educated platelets of patients with active NSCLC do not contain enough tumor-derived mRNA molecules to detect therapy-guiding mutations with a sensitivity required in a diagnostic setting. (this thesis)
3. Initial concurrent mutations of genes in the PI3K or MAPK pathways with BRAF p.(V600E) does not predict a worse PFS of combined dabrafenib and trametinib treatment. (this thesis)
4. Combination of dabrafenib and trametinib concurrently with osimertinib is a promising treatment strategy for EGFR-mutant patients with a BRAF p.(V600E) resistance mutation. (this thesis)
5. High EGFR copy numbers as determined by amplicon-based NGS data predict a worse overall survival in EGFR mutated patients treated with first-line EGFR-TKI, especially in those who developed a T790M mutation. (this thesis)
6. Circulating tumor DNA levels in low disease-stage ESCC patients are associated with tumor load in real-time, and may be used to monitor disease load. (this thesis)
7. The challenge of tumor heterogeneity should not discourage or intimidate efforts to overcome cancer but should push the field forward. (Seung Ho Shin et al. NPJ Precis Oncol, 2017)
8. That which does not kill us makes us stronger. (Friedrich Nietzsche)
9. Great things in research are never done by one person. They're done by a team of people. (Adapted from Steven Jobs)
10. Busy is a choice. Stress is a choice. Joy is a choice. Choose well. (Ann Voskamp)